Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Shennan Circuits Co Ltd
SZSE:002916
|
CN |
|
C
|
Chongqing VDL Electronics Co Ltd
SZSE:301121
|
CN |
|
Saudi Vitrified Clay Pipe Company SJSC
SAU:2360
|
SA |
|
S
|
Sling Group Holdings Ltd
HKEX:8285
|
HK |
Biotron Ltd
Total Liabilities & Equity
Biotron Ltd
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Total Liabilities & Equity
AU$3.9m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities & Equity
$782.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
0%
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities & Equity
$37.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Liabilities & Equity
AU$24.8m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities & Equity
AU$1.2B
|
CAGR 3-Years
66%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities & Equity
AU$159.1m
|
CAGR 3-Years
71%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
3.9m
AUD
Based on the financial report for Dec 31, 2025, Biotron Ltd's Total Liabilities & Equity amounts to 3.9m AUD.
What is Biotron Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
1%
Over the last year, the Total Liabilities & Equity growth was 301%. The average annual Total Liabilities & Equity growth rates for Biotron Ltd have been -17% over the past three years , -6% over the past five years , and 1% over the past ten years .
